Bruton's Tyrosine Kinase (BTK) has a pivotal role in the BCR signalling pathway which is upregulated in B cell malignancies. Activation is dependent on two phosphorylation events, at Y551 and Y223 in the kinase and SH3 domains respectively. Of the remaining three domains, the Pleckstrin Homology (PH) domain is essential for the membrane recruitment which allows for phosphorylation. Conventional therapies target the ATP binding site in the kinase domain, specifically residue C481, to prevent BTK activation. However, this region is relatively conserved across the kinome and prolonged use leads to resistance and relapse as patients develop a C481S mutation. To overcome these issues, this project aims to exploit fragment-based drug discovery (FBDD) against the PH domain. Literature precedent justifies targeting this domain, which proved effective for a similar protein (AKT), as well as utilising FBDD against proteins with a significant role in cancer (CK2). Fragment elaboration led to a parent compound and the project is now well-established with three generations of compounds already synthesised by linking two hit fragments. Further generations of analogues will be synthesised and tested, using a synthetic route in need of optimisation. The scaffold will be investigated by replacing the ketone and phenyl groups and measuring affinity. Biochemical validation will be achieved in collaboration with the Hyvönen Group through mass spectrometry, differential scanning fluorimetry (DSF), X-ray crystallography and fluorescence polarisation (FP). Since the compounds are enantiomeric, key analogues will be sent to Astra Zeneca for separation. Testing the enantiomers individually in conjunction with molecular modelling and covalent docking will help deduce whether their binding affinities are competitive. Biological approaches to confirm inhibition will be investigated given the available facilities, but could include GFP-tagging, immunoprecipitation and blotting or flow...
This is one of 1,833 active United Kingdom Research Development opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start Free| Issuing agency | EPSRC |
|---|
| Country | United Kingdom |
|---|
| Category | Research Development |
|---|
| Published | September 30, 2022 |
|---|
| Procurement stage | Active solicitation |
|---|
| Response due | September 29, 2026 |
|---|
| Status | Open — accepting responses |
|---|
| Official source | View original notice |
|---|
| Last verified | August 09, 2026 |
|---|
Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.
See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Used by capture teams who win by looking where the big players aren’t.
Get a free United Kingdom Research Development intelligence report in your inbox
A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.